About

Milestone and History

  • 2024

    April
    Received Taiwan FDA approval to initiate Phase 2 clinical trials for SHJ002-SJP, a nucleic acid drug for treating corneal damage in Sjogren’s patients.
    Completed the unblinding of SHJ002-DED Phase 2 clinical trial for dry eye disease. Statistical results showed significantly higher recovery scores in the treatment group compared to the placebo group, with statistically significant differences (p-value = 0.001).

    March
    Completion of the registration for the merger with Dreamhawk Vision Biotech, Inc. Issued new shares worth $18,645,893 USD for the merger and retired shares worth NT$189,487,000, resulting in paid-in capital of NT$617,181,590.

    January
    Processing the merge of Dreamhawk Vision Biotech, Inc. with Sunhawk Vision Biotech, Inc.. Sunhawk would remain as the surviving entity. The merger date was set as February 5, 2024.

  • 2023

    September
    Received approval from the Taiwan FDA to initiate Phase 2 clinical trials for SHJ002-DED, a nucleic acid drug for treating dry eye disease.

    March
    Granted a Taiwanese invention patent for SHJ002-DED for treating dry eye disease (“Method for treating ocular surface diseases” Patent No. I796875).

    January
    Initiated Phase 2 clinical trials of SHJ002-DED, a nucleic acid drug for treating Dry Eye Disease in Thailand.

    2023

  • 2022

    October
    Initiated Phase 2 clinical trials of SHJ002-DED, a nucleic acid drug for treating Dry Eye Disease in Australia.

    July
    Won the “Innovation Technology Award” at the Taipei Biotechnology Awards.

    April
    SHJ002-MY Phase 1 pediatric myopia clinical trial passed the Ministry of Health and Welfare’s GCP inspection with zero deficiencies.

    January
    Completed Phase 1 clinical trials for SHJ002-MY in pediatric myopia.
    Raised NT$50 million through cash investment, increasing the paid-in capital to NT$211 million.

  • 2021

    February
    Received unconditional, no-objection approval from the U.S. FDA for the first-in-class drug SHJ002 to proceed with clinical trials.

    2021

  • 2020

    October
    Won the “Breakthrough and Emerging Startups Award” from the Ministry of Economic Affairs, Taiwan.

    January
    Raised NT$70,150,393 through cash investment, increasing the paid-in capital to NT$161 million.

  • 2019

    November
    Raised NT$70 million through a technology transfer, increasing the paid-in capital to NT$90,846,070.

    October
    Acquired the technology transfer and intellectual property rights for “Use of RNA interference in manufacturing a medicament for treating and/or preventing myopia” from Kaohsiung Medical University for global use.

    September
    Acquired the technology transfer rights for “anti-myopia eye drop SHJ002 preclinical data” from China Medical University for global use.

    August
    Sunhawk Vision Biotech, Inc., was officially established with a capital of NT$20,846,070.

    2019

Kaohsiung Office

Taipei Office

© Copyright – Sunhawk Vision Biotech, Inc.

design by Morcept

© Copyright – Sunhawk Vision Biotech, Inc.
design by Morcept